McNeil Recalls Cut J&J's Profits, Draw U.S. Attorney's Subpoena

Investment analysts are confident in Johnson & Johnson's long-term viability even though recalls of OTC drugs and the temporary closure of the facility where the products were made prompted the firm to slash full-year profits estimates and triggered a federal investigation